comprehensive -WSS

comprehensive

author：leisure time 2025-08-23 06:47:06 - browse：9

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： RSV shot was 90% effective at preventing hospitalizations in kids

WSS

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Headspace, Meta partner to launch VR meditation app for Quest

Study points to new risk in gene therapy death of Terry Horgan

First medicine developed to treat MASH expected to be approved soon

The drug industry has found itself all alone in Washington

The Readout: Amylyx, Alumis, and Lundbeck drug updates

focus

comprehensive

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Study points to new risk in gene therapy death of Terry Horgan

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Precocious puberty in girls comes with mental health risks

Moonlake's readout produced a cash windfall. Risks remain

Health insurers' Q3 question: how much care are people getting?

What does generative AI mean for health care? We asked experts

NEJM study link tiny plastics in blood vessels to heart problems

Trump demands the U.S. pay no more for drugs than other countries … again

The Readout: Amylyx, Alumis, and Lundbeck drug updates

focus

The problem with charging patients to message their doctors

With psoriasis trial ahead, Alumis raises $259 million

Amylyx ALS drug fails large clinical trial

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Change Healthcare cyberattack prompts Medicare loan program

The Readout: Amylyx, Alumis, and Lundbeck drug updates

focus

focus

hotspot

focus